Dose adjustment study for adalimumab in pediatric uveitis
Part of Eyes & vision clinical trials.
This study tests whether adjusting the dose of adalimumab (a medicine that helps control inflammation) can keep eye inflammation and joint symptoms under control in children and young adults with JIA or chronic anterior uveitis. If you have been stable on adalimumab for a long time, this trial may help find the best dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 2 years old and weigh at least 15 kg.
- You must have had juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (eye inflammation) diagnosed before you turned 16.
- Your eye inflammation and arthritis must have been well controlled for at least 24 months (2 years) without needing stronger treatment.
- You must have been on a stable dose of adalimumab (or a biosimilar) for at least 6 months, with no dose changes.
- You cannot have used steroid eye drops, oral steroids, or steroid injections in the past 3 to 6 months.
- You cannot have had recent eye surgery, active cancer, tuberculosis, or hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to check for eye inflammation (uveitis) in children with juvenile idiopathic arthritis (JIA) using imaging instead of regular eye exams. It may help catch eye problems early and make screening easier for kids.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This trial tests whether people with chronic uveitis (eye inflammation) who have been stable on adalimumab (a biologic medicine) for at least 24 weeks can safely reduce their dose. The goal is to see if a lower dose can still control the inflammation while reducing side effects and costs.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Hear when a new Uveitis, Anterior trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.